- Home
- PLRX vs TCRX Comparison
PLRX vs TCRX Comparison
Compare PLRX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- TCRX
- Stock Information
- Founded
- PLRX 2015
- TCRX 2018
- Country
- PLRX United States
- TCRX United States
- Employees
- PLRX N/A
- TCRX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- TCRX Health Care
- Exchange
- PLRX Nasdaq
- TCRX Nasdaq
- Market Cap
- PLRX 90.9M
- TCRX 90.5M
- IPO Year
- PLRX 2020
- TCRX 2021
- Fundamental
- Price
- PLRX $1.41
- TCRX $1.27
- Analyst Decision
- PLRX Hold
- TCRX Strong Buy
- Analyst Count
- PLRX 10
- TCRX 7
- Target Price
- PLRX $9.79
- TCRX $9.86
- AVG Volume (30 Days)
- PLRX 726.8K
- TCRX 389.5K
- Earning Date
- PLRX 05-08-2025
- TCRX 05-06-2025
- Dividend Yield
- PLRX N/A
- TCRX N/A
- EPS Growth
- PLRX N/A
- TCRX N/A
- EPS
- PLRX N/A
- TCRX N/A
- Revenue
- PLRX N/A
- TCRX $4,421,000.00
- Revenue This Year
- PLRX N/A
- TCRX $47.30
- Revenue Next Year
- PLRX N/A
- TCRX $74.30
- P/E Ratio
- PLRX N/A
- TCRX N/A
- Revenue Growth
- PLRX N/A
- TCRX N/A
- 52 Week Low
- PLRX $1.10
- TCRX $1.02
- 52 Week High
- PLRX $16.52
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- PLRX 39.44
- TCRX 37.62
- Support Level
- PLRX $1.36
- TCRX $1.32
- Resistance Level
- PLRX $1.72
- TCRX $1.65
- Average True Range (ATR)
- PLRX 0.11
- TCRX 0.12
- MACD
- PLRX 0.04
- TCRX -0.02
- Stochastic Oscillator
- PLRX 13.89
- TCRX 0.00
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.